145 related articles for article (PubMed ID: 28900847)
1. Effect of rituximab on primary central nervous system lymphoma: a meta-analysis.
Song Y; Wen Y; Xue W; Zhang Y; Zhang M
Int J Hematol; 2017 Nov; 106(5):612-621. PubMed ID: 28900847
[TBL] [Abstract][Full Text] [Related]
2. Role of Rituximab in Treatment of Patients With Primary Central Nervous System Lymphoma (PCNSL): A Systematic Review and Meta-Analysis.
Zhang Y; Liu Z; Gao C; Bian H; Ma Y; Jing F; Zhao X
Clin Lymphoma Myeloma Leuk; 2023 Oct; 23(10):733-741. PubMed ID: 37453867
[TBL] [Abstract][Full Text] [Related]
3. Role of rituximab in treatment of patients with primary central nervous system lymphoma: a retrospective analysis of the Czech lymphoma study group registry.
Mocikova H; Pytlik R; Sykorova A; Janikova A; Prochazka V; Vokurka S; Berkova A; Belada D; Campr V; Buresova L; Trneny M;
Leuk Lymphoma; 2016 Dec; 57(12):2777-2783. PubMed ID: 27087066
[TBL] [Abstract][Full Text] [Related]
4. The influence of rituximab, high-dose therapy followed by autologous stem cell transplantation, and age in patients with primary CNS lymphoma.
Madle M; Krämer I; Lehners N; Schwarzbich M; Wuchter P; Herfarth K; Egerer G; Ho AD; Witzens-Harig M
Ann Hematol; 2015 Nov; 94(11):1853-7. PubMed ID: 26268792
[TBL] [Abstract][Full Text] [Related]
5. Rituximab in primary central nervous system lymphoma-A systematic review and meta-analysis.
Schmitt AM; Herbrand AK; Fox CP; Bakunina K; Bromberg JEC; Cwynarski K; Doorduijn JK; Ferreri AJM; Illerhaus G; Issa S; Schorb E; Zucca E; Hemkens LG; Schandelmaier S; Kasenda B
Hematol Oncol; 2019 Dec; 37(5):548-557. PubMed ID: 31418878
[TBL] [Abstract][Full Text] [Related]
6. TP53 hotspot mutations are predictive of survival in primary central nervous system lymphoma patients treated with combination chemotherapy.
Munch-Petersen HD; Asmar F; Dimopoulos K; Areškevičiūtė A; Brown P; Girkov MS; Pedersen A; Sjö LD; Heegaard S; Broholm H; Kristensen LS; Ralfkiaer E; Grønbæk K
Acta Neuropathol Commun; 2016 Apr; 4():40. PubMed ID: 27101868
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of the Nordic and the MSKCC chemotherapy protocols on the overall and progression-free survival in intracranial PCNSL.
Da Broi M; Jahr G; Beiske K; Holte H; Meling TR
Blood Cells Mol Dis; 2018 Nov; 73():25-32. PubMed ID: 30217760
[TBL] [Abstract][Full Text] [Related]
8. Effect of rituximab on adult Burkitt's lymphoma: a systematic review and meta-analysis.
Nie M; Wang Y; Bi XW; Xia Y; Sun P; Liu PP; Li ZM; Jiang WQ
Ann Hematol; 2016 Jan; 95(1):19-26. PubMed ID: 26423805
[TBL] [Abstract][Full Text] [Related]
9. The Efficacy and Safety of Cytarabine on Newly Diagnosed Primary Central Nervous System Lymphoma: A Systematic Review and Meta-Analysis.
Zheng X; Yang S; Chen F; Wu S; Li W
Front Oncol; 2020; 10():1213. PubMed ID: 32903796
[No Abstract] [Full Text] [Related]
10. The Role of Rituximab in Primary Central Nervous System Lymphoma.
Bromberg JEC; van der Meulen M; Doorduijn JK
Curr Oncol Rep; 2020 Jun; 22(8):78. PubMed ID: 32602069
[TBL] [Abstract][Full Text] [Related]
11. Pemetrexed for primary central nervous system lymphoma in the elderly.
Han S; Wang M; Liu B; Yu J
Clin Transl Oncol; 2016 Feb; 18(2):138-43. PubMed ID: 26169215
[TBL] [Abstract][Full Text] [Related]
12. Rituximab with high-dose methotrexate in primary central nervous system lymphoma.
Kansara R; Shenkier TN; Connors JM; Sehn LH; Savage KJ; Gerrie AS; Villa D
Am J Hematol; 2015 Dec; 90(12):1149-54. PubMed ID: 26414492
[TBL] [Abstract][Full Text] [Related]
13. Pemetrexed plus rituximab as second-line treatment for primary central nervous system lymphoma.
Zhao HT; Chen J; Shi SB; Tian J; Tao RJ
Med Oncol; 2015 Jan; 32(1):351. PubMed ID: 25428379
[TBL] [Abstract][Full Text] [Related]
14. Treatment of newly diagnosed B-cell origin primary CNS lymphoma with systemic R-IDARAM chemotherapy and intrathecal immunochemotherapy.
Qian L; Zhou C; Shen J; Cen J; Yin W
Oncotarget; 2016 May; 7(18):25783-90. PubMed ID: 27029056
[TBL] [Abstract][Full Text] [Related]
15. MMSE is an independent prognostic factor for survival in primary central nervous system lymphoma.
van der Meulen M; Dirven L; Bakunina K; van den Bent MJ; Issa S; Doorduijn JK; Bromberg JEC
J Neurooncol; 2021 Apr; 152(2):357-362. PubMed ID: 33611761
[TBL] [Abstract][Full Text] [Related]
16. The role of ABCB1 polymorphism as a prognostic marker for primary central nervous system lymphoma.
Wu T; Kang H; Zhuang D; Ma Y; Lin Z; Suolitiken D; Chen B; Xu X
Ann Hematol; 2019 Apr; 98(4):923-930. PubMed ID: 30729282
[TBL] [Abstract][Full Text] [Related]
17. Interim
Jo JC; Yoon DH; Kim S; Lee K; Kang EH; Park JS; Ryu JS; Huh J; Park CS; Kim JH; Lee SW; Suh C
Ann Hematol; 2017 Sep; 96(9):1509-1515. PubMed ID: 28725988
[No Abstract] [Full Text] [Related]
18. Immunochemotherapy with rituximab and temozolomide for central nervous system lymphomas.
Wong ET; Tishler R; Barron L; Wu JK
Cancer; 2004 Jul; 101(1):139-45. PubMed ID: 15221999
[TBL] [Abstract][Full Text] [Related]
19. Treatment of secondary central nervous system lymphoma with intrathecal rituximab, high-dose methotrexate, and R-DHAP followed by autologous stem cell transplantation: results of the HOVON 80 phase 2 study.
Doorduijn JK; van Imhoff GW; van der Holt B; Schouten HC; Schaafsma MR; MacKenzie MA; Baars JW; Kersten MJ; Lugtenburg PJ; van den Bent MJ; Enting RH; Spoelstra FM; Poortmans P; Bromberg JEC
Hematol Oncol; 2017 Dec; 35(4):497-503. PubMed ID: 27530779
[TBL] [Abstract][Full Text] [Related]
20. A focus on pharmacotherapy for primary central nervous system lymphoma.
Korfel A
Expert Rev Hematol; 2015 Oct; 8(5):559-62. PubMed ID: 26159859
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
